Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
NKGen Biotech, Inc. - Common Stock
(NQ:
NKGN
)
0.1913
UNCHANGED
Last Price
Updated: 4:00 PM EST, Mar 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
0.1913
Bid (Size)
0.1900 (4)
Ask (Size)
0.1901 (279)
Prev. Close
0.1913
Today's Range
0.1913 - 0.1913
52wk Range
0.1913 - 0.9649
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
March 04, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented
March 04, 2025
From
NKGen Biotech
Via
GlobeNewswire
Performance
YTD
-72.3%
-72.3%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
-52.2%
-52.2%
More News
Read More
NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program
March 03, 2025
From
NKGen Biotech
Via
GlobeNewswire
Wondering what's happening in today's pre-market session?
February 24, 2025
Via
Chartmill
These stocks are the most active in today's session
February 21, 2025
Via
Chartmill
Gapping stocks in Friday's session
February 21, 2025
Via
Chartmill
These stocks are moving in today's pre-market session
February 21, 2025
Via
Chartmill
NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
February 21, 2025
From
NKGen Biotech
Via
GlobeNewswire
NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease with AdventHealth Orlando as First East Coast Site
February 19, 2025
From
NKGen Biotech
Via
GlobeNewswire
Top movers in Friday's pre-market session
February 14, 2025
Via
Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 14, 2025
Via
Benzinga
Get insights into the top gainers and losers of Thursday's after-hours session.
February 13, 2025
Via
Chartmill
The trading volume of these stocks is deviating from the norm in today's session.
February 13, 2025
Via
Chartmill
Which stocks are moving on Thursday?
February 13, 2025
Via
Chartmill
Thursday's session: gap up and gap down stocks
February 13, 2025
Via
Chartmill
Thursday's pre-market session: top gainers and losers
February 13, 2025
Via
Chartmill
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease
February 13, 2025
From
NKGen Biotech
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 13, 2025
Via
Benzinga
Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket
February 13, 2025
Via
Benzinga
Keep an eye on the top gainers and losers in Wednesday's session.
February 12, 2025
Via
Chartmill
Traders are paying attention to the gapping stocks in Wednesday's session.
February 12, 2025
Via
Chartmill
Wednesday's pre-market session: top gainers and losers
February 12, 2025
Via
Chartmill
NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s Disease
February 12, 2025
From
NKGen Biotech
Via
GlobeNewswire
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
December 02, 2024
From
NKGen Biotech, Inc.
Via
GlobeNewswire
NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel
November 26, 2024
From
NKGen Biotech, Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is NKGen Biotech, Inc. - Common Stock publicly traded?
Yes, NKGen Biotech, Inc. - Common Stock is publicly traded.
What exchange does NKGen Biotech, Inc. - Common Stock trade on?
NKGen Biotech, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for NKGen Biotech, Inc. - Common Stock?
The ticker symbol for NKGen Biotech, Inc. - Common Stock is NKGN on the Nasdaq Stock Market
What is the current price of NKGen Biotech, Inc. - Common Stock?
The current price of NKGen Biotech, Inc. - Common Stock is 0.1913
When was NKGen Biotech, Inc. - Common Stock last traded?
The last trade of NKGen Biotech, Inc. - Common Stock was at 03/04/25 04:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.